Can you explain how you know CHF will be lucrative? (i.e. cost of treatment, number of treatments... likely commercial uptake). GVHD treatment is worth every cent, it provides a cure for life. Phase 2 CHF didn't provide the miracle LV remodelling and increases in ejection fraction that was hoped, It only showed beneficial in a surrogate end point of MACE in a small subset. Its health economics, no one will pay big money (over one hundred thousand dollars probably) for a treatment that doesn't provide for a long disease free period. The placement of an implantable defibrillator in the same population (at much less cost) provides far greater benefit.
Ann: Update on Global Heart Failure Program-MSB.AX, page-168
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.13 |
Change
-0.055(4.66%) |
Mkt cap ! $1.284B | |||
| Open | High | Low | Value | Volume |
| $1.18 | $1.18 | $1.13 | $4.824M | 4.236M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 25589 | $1.13 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.13 | 10000 | 1 |
View Market Depth
| Last trade - 16.10pm 17/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |